Search - tctmd.com

Displaying 21 - 40 of 76

Sort: Relevancy | Date

Tendyne Approved in US for High-risk Patients With Mitral Valve Disease

News Daily News

Tendyne Approved in US for High-risk Patients With Mitral Valve Disease

Michael O'Riordan

May 28, 2025

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

News Daily News EuroPCR 2025

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

Michael O'Riordan

May 28, 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis

News Conference News EuroPCR 2025

Higher Mortality With TAVI Over Surgery in Bicuspid Aortic Stenosis

Michael O'Riordan

May 22, 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

News Conference News EuroPCR 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Michael O'Riordan

May 21, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity

News Conference News European Congress on Obesity 2025

Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity

Michael O'Riordan

May 16, 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

News Conference News European Congress on Obesity 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

Tirzepatide Tops Semaglutide for Weight Loss SURMOUNT-5

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

News Daily News

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Michael O'Riordan

May 02, 2025

Donor Hearts Fare Better With Novel Method After Circulatory Death

News Daily News

Donor Hearts Fare Better With Novel Method After Circulatory Death

Michael O'Riordan

May 01, 2025

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

Weekend Warriors Also See Mortality Benefits With Exercise

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.